PlainPill

Methylphenidate

Also known as Ritalin, Concerta

The short answer. Most people who report on Methylphenidate say it did not help (only 39% of 352 positive). It is most often used for focus: 83% of 262 reports say that improved. It is well studied — 383 meta-analyses on PubMed. The most common complaint is anxiety.

What users report
39%helped352 reports · high confidence
136 helped125 mixed91 didn't help

From 567 mentions in total — the rest didn't say how it went and aren't counted.

Clinical research
AStrong research base
383
meta-analyses
1,123
RCTs
9,061
papers
Prescription medication. These are self-reported experiences, not dosing or treatment advice. Prescription drugs have real side effects and interactions — start, stop or change them only with a doctor. Share of positive reports is not a measure of safety.

What Methylphenidate does, according to users

Of the people who reported each effect, the share who said it got better.

What the research says

Systematic reviews and meta-analyses from PubMed, with their published conclusions.

AStrong research base

3+ meta-analyses or systematic reviews and 10+ randomized controlled trials in humans. The grade measures how much human research exists — read the conclusions below for what it found. 383 meta-analyses on PubMed ↗ · 1,123 randomized trials ↗

Lancet Psychiatry · 2018 · Meta-analysis / systematic review
Comparative efficacy and tolerability of medications for attention-deficit hyperactivity disorder in children, adolescents, and adults: a systematic review and network meta-analysis

Conclusion: Our findings represent the most comprehensive available evidence base to inform patients, families, clinicians, guideline developers, and policymakers on the choice of ADHD medications across age groups. Taking into account both efficacy and safety, evidence from this meta-analysis supports methylphenidate in children and adolescents, and amphetamines in adults, as preferred first-choice medications for the short-term treatment of ADHD. New research should be funded urgently to assess long-term effects of these drugs.

PubMed 30097390 ↗
J Am Acad Child Adolesc Psychiatry · 2025 · Meta-analysis / systematic review
Systematic Review and Meta-Analysis: Effects of Pharmacological Treatment for Attention-Deficit/Hyperactivity Disorder on Quality of Life

Conclusion: In addition to being efficacious in reducing ADHD core symptom severity, both stimulant and nonstimulant medications are efficacious in improving QoL in people with ADHD, albeit with lower effect sizes. Future research should explore whether, and to what degree, combining pharmacological and nonpharmacological interventions is likely to further improve QoL in people with ADHD.

PubMed 38823477 ↗
PLoS One · 2020 · Meta-analysis / systematic review
Pharmacologic treatment of attention deficit hyperactivity disorder in adults: A systematic review and network meta-analysis

Conclusion: Overall, despite a class effect of improving clinical response relative to placebo, there were few differences among the individual ADHD pharmacotherapies, and most studies were at risk of at least one important source of bias. Furthermore, the certainty of the evidence was very low to low for all outcomes, and there was limited reporting of long-term adverse events. As such, the choice between ADHD pharmacotherapies may depend on individual patient considerations, and future studies should assess the long-term effects of individual pharmacotherapies on patient-important outcomes, including qu

PubMed 33085721 ↗
J Head Trauma Rehabil · 2021 · Meta-analysis / systematic review
Pharmacological Treatment of Agitation and/or Aggression in Patients With Traumatic Brain Injury: A Systematic Review of Reviews

Conclusion: On the basis of the results of this literature review, the authors recommend avoiding benzodiazepines and haloperidol for treating agitation and/or aggression in the context of TBI. Atypical antipsychotics (olanzapine in particular) can be considered as practical alternatives for the as-needed management of agitation and/or aggression in lieu of benzodiazepines and haloperidol. Amantadine, β-blockers (propranolol and pindolol), antiepileptics, and methylphenidate can be considered for scheduled treatment of agitation and/or aggression in patients with TBI.

PubMed 33656478 ↗
Registered clinical trials

539 human trials on ClinicalTrials.gov test Methylphenidate — 346 completed, 38 recruiting now. See all on ClinicalTrials.gov ↗

What government agencies say

Official records from US, Canadian and EU regulators, each linked to its source.

US legal status (DEA)

Methylphenidate is a Schedule II controlled substance in the US. DEA controlled-substance list ↗

FDA drug label

Boxed warning (the FDA's strongest label warning): “ABUSE, MISUSE, AND ADDICTION Methylphenidate hydrochloride extended-release tablets have a high potential for abuse and misuse, which can lead to the development of a substance use disorder, including addiction. Misuse and abuse of CNS stimulants, including methylphenidate hydrochloride…”

Full label on DailyMed (NIH) ↗

FDA recalls

55 recalls of products named for Methylphenidate. Most recent:

  • 2024-07-10 · Class II: Failed dissolution specifications: this product is being recalled due to this batch not meeting dissolution specifications. record ↗
  • 2023-08-02 · Class II: Presence of Foreign Substance: Metal embedded in a tablet. record ↗
  • 2023-03-29 · Class II: Defective Delivery System: Out of specification for shear. record ↗

Class I = could cause serious harm; Class II = temporary or reversible harm; Class III = unlikely to cause harm. Recalls are of specific products and lots, not of the ingredient itself. All recalls (openFDA) ↗

Reports to the FDA about the drug (FAERS)

73,102 adverse-event reports mention Methylphenidate. Most often reported:

  • Off label use · 7,799
  • Drug ineffective · 7,512
  • No adverse event · 7,043
  • Product quality issue · 5,591
  • Fatigue · 3,318
  • Headache · 3,169

Reports often involve several drugs and serious illness; a report doesn't prove the drug caused the problem, and these counts can't tell you how often it happens. Source query (openFDA) ↗

Liver safety (LiverTox, NIH)

LiverTox rates Methylphenidate C — a probable rare cause of liver injury (3–12 published cases). LiverTox entry ↗

US government research funding (NIH)

NIH has funded 89 research projects with Methylphenidate in the title, $75,383,530 in total (1985–2026). NIH RePORTER ↗

Plain-language guides from the US government: MedlinePlus: Methylphenidate ↗

Dosage people report

We don't list doses for prescription medications. Dosing should only come from a doctor or pharmacist.

Reported side effects

How often each side effect came up across all reports.

anxiety ×33jitteriness ×22insomnia ×19fatigue ×16drowsiness ×6irritability ×5emotional blunting ×2mania ×2

What users say

First-hand experiences, quoted verbatim. We show one positive and one negative where both exist.

“I tried both ritalin worked way better in me like way better.”
HelpedRead the discussion ↗
“I take methylphenidate and it’s changed my life for the way way better.”
MixedRead the discussion ↗
“I got diagnosed with ADHD and tried Ritalin and Elvanse and they do help somewhat when I need to learn for an exam but I hate the feeling of being on them.”
MixedRead the discussion ↗
“Concerta, Vyvanse (they gave me stimulation and a mood booster but it felt really artificial, left me with more depression when I was not taking it)”
Didn't helpRead the discussion ↗
Read more Methylphenidate reviews →
Top discussions (5)

Methylphenidate compared

Other options for focus

Sources

User data from public discussions; research from PubMed. Information only, not medical advice — talk to a doctor before starting, stopping or combining anything. Data updated October 5, 2026. How we rate